Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT06077760 |
| Title | A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002) (INTerpath-002) |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase III |
| Variant Requirements | No |
| Sponsors | Merck Sharp & Dohme LLC |
| Indications | |
| Therapies | |
| Age Groups: | senior | adult |
| Covered Countries | USA | TUR | SVK | POL | NZL | NOR | LVA | LTU | ITA | IRL | HUN | GRC | FRA | FIN | EST | ESP | DNK | DEU | CZE | CAN | BRA | BEL | AUS | ARG |